MSH6 and neoplasm: Even though we cannot clarify the loss of MSH6 expression in this case without detected MSH6 mutations or pre-treatment, it is already known that IHC findings do not always completely overlap with NGS results (46, 47), which may be due to methodical issues like the used NGS panel or the amount of tumor tissue for NGS but also due to biologic reasons, such as epigenetic regulation of expression.